Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 7, 2025
Management Tracks
Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus
Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Feb 11, 2025
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Jan 30, 2025
Management Tracks
Wyman joins Scholar Rock
Plus: Danilkowicz to lead commercial at Alumis and an update from Precision
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Nov 19, 2024
Product Development
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
BioCentury | Oct 21, 2024
Product Development
EGFR: A best-in-class strategy study
The target is one of industry’s most notable case studies in continued product differentiation and market growth
BioCentury | Oct 9, 2024
Product Development
TYK2 best-in-class battleground expands with InnoCare data
In BioCentury’s latest Clinical Report: Sage misses in early Alzheimer’s, and a Phase III setback for J&J’s bladder cancer delivery device
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Aug 6, 2024
Finance
With an eye toward ‘inflection capital’ for biotechs, TPG focuses new fund on clinical POC
Firm has $580M in to invest in life sciences strategy
Items per page:
1 - 10 of 111